6.7.15. guidelines supportive care castrate-resistant disease. recommendations addition appropriate systemic therapy. recommendationsstrength ratingoffer bone protective agents patients metastatic prostate cancer skeletal metastases prevent osseous complications.strongmonitor serum calcium offer calcium vitamin supplementation prescribing either denosumab bisphosphonates.strongtreat painful bone metastases early palliative measures intensity-modulated radiation therapy/volumetric arc radiation therapy plus image-guided radiation therapy adequate use analgesics.strongin patients spinal cord compression start immediate high-dose corticosteroids assess spinal surgery followed irradiation. offer radiation therapy alone surgery appropriate.strong figure 6.4: treatment non-metastasized (m0) – asymptomatic disease * rule thumb: life expectancy ten years.** recommendation based clinical staging using digital rectal examination, imaging.*** recommendation based staging using combination bone scan ct.**** see text, dependent gg (biopsy) volume. 1ebrt: imrt/vmat + igrt prostate. █ (light green) = weak recommendation. adt = androgen deprivation therapy; ebrt =external beam radiotherapy; ece = extracapsular extension; eplnd = extended pelvic lymph node dissection; gg = grade group; hdr = high-dose rate; idc = intraducal carcinoma; igrt = image-guided radiotherapy; imrt = intensity-modulated radiotherapy; ldr = low-dose rate; vmat = volumetric modulated arc therapy. figure 6.5: treatment metastasized (m1*) – disease, m+hspc * based staging using combination bone scan ct.** alphabetical order.***not low volume, metachronous disease.1ebrt: imrt/vmat + igrt prostate (equivalent 72 gy 2 gy fractions). █ (light green) = weak recommendation. ebrt = external beam radiotherapy; igrt = image-guided radiotherapy; imrt = intensity-modulated radiotherapy. #note: please aware various options following flowcharts present generalised approach only, cannot take management individual patients account, availability resources.